Loading...
XT logo

iShares Trust - iShares Future Exponential Technologies ETFNasdaqGM:XT Aktienübersicht

Marktkapitalisierung US$3.9b
Aktienkurs
US$82.28
Mein Marktwert
n/v
1Y30.8%
7D2.3%
1D
Wert des Portfolios
​
Siehe

iShares Trust - iShares Future Exponential Technologies ETF

NasdaqGM:XT Lagerbericht

Marktkapitalisierung: US$3.9b

iShares Trust - iShares Future Exponential Technologies ETF (XT) Aktienübersicht

iShares Trust - iShares Future Exponential Technologies ETF ist ein börsengehandelter Fonds, der von BlackRock, Inc. Mehr Details

XT grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung0/6
Künftiges Wachstum0/6
Vergangene Leistung0/6
Finanzielle Gesundheit0/6
Dividenden2/6

XT Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

iShares Trust - iShares Future Exponential Technologies ETF Wettbewerber

 
 
 
 
 
 
 
 
 
 
 
 

Preisentwicklung & Leistung

Zusammenfassung der Höchst- und Tiefststände sowie der Veränderungen der Aktienkurse für iShares Trust - iShares Future Exponential Technologies ETF
Historische Aktienkurse
Aktueller AktienkursUS$82.28
52-Wochen-HochUS$84.23
52-Wochen-TiefUS$62.03
Beta0
1 Monat Veränderung3.99%
3 Monate Veränderung19.33%
1 Jahr Veränderung30.79%
3 Jahre Veränderung48.38%
5 Jahre Veränderung31.94%
Veränderung seit IPO219.53%

Aktuelle Nachrichten und Updates

Seeking Alpha • Apr 10

XT: More Sensitive Than General Market To Cost Of Capital Changes

Summary The iShares Future Exponential Technologies ETF is highly sensitive to cost of capital shifts, driven by its tech and disruptor focus, also with a lot of high-multiple healthcare. XT's global diversification does not mitigate its vulnerability to rising rates and geopolitical risks, especially from the Iran conflict, which is having a global upward cost of capital shift effect. XT is less concentrated in mega-cap US tech than IVV, but its higher IT and healthcare exposure increases sensitivity to inflation and capital costs and maintains sensitivity to overbuild risks. We see more risks than supports for XT, given fragile geopolitics and amplified yield curve sensitivity. Lower multiple alternatives in equity markets often present less cost of capital sensitivity. Read the full article on Seeking Alpha
Seeking Alpha • Oct 06

XT: An Undervalued Portfolio Of Innovative Global Tech Stocks

Summary iShares Exponential Technologies ETF focuses on companies driving technological innovation across various sectors, offering diversified exposure to high-growth potential industries. The ETF's investment thesis is centered on capturing the growth of exponential technologies, including AI, robotics, and biotechnology, which are expected to transform industries. The fund looks appealing due to its diversified portfolio, evidential capacity to out-perform (albeit not since January 2021), and alignment with long-term technological trends. At present, XT has clear potential for a high IRR, with the potential for returns of circa 11% annualized over the next five years. Read the full article on Seeking Alpha
Seeking Alpha • Jun 07

XT Will Likely Continue Lagging The Broader IT Sector

Summary iShares Exponential Technologies ETF is a hold due to multiple risk factors outweighing its returns along with a relatively high expense ratio. XT lacks holdings with strong fundamentals and diversified revenue streams compared to peer tech funds, particularly Vanguard's VGT. XT also includes foreign tech holdings in emerging markets, representing geopolitical risks. Read the full article on Seeking Alpha
Seeking Alpha • Mar 10

XT: Still Beating ARKK At Its Own Game, Upgrade To Buy For Possible Moonshot

Summary iShares Exponential Technologies ETF is a go-to holding due to market volatility and potential for high returns. I prefer XT to the ARK Innovation ETF, given its smoother path due to a more diversified and passive/indexed approach. XT's lower volatility and diversified portfolio make it a buy, with potential for a price increase to its 2022 high and beyond. Read the full article on Seeking Alpha
Seeking Alpha • Aug 07

XT: We're Going To Think Twice About This ETF

XT is pretty interesting and tackles an area of the market that has received flak in the latest sell-offs. However, we have some concerns about approaching emerging technologies with ETFs. Also the fund isn't that discounted despite expected reflexivity effects. Might get better bets with specific stocks. The iShares Exponential Technologies ETF (XT) might seem broadly interesting at first, but we have some misgivings about the concept of investing in ETFs of higher risk businesses. Moreover, we are surprised by how well the ETF has done all things considered, and worry that some latent effects might still hit it. Otherwise, we are pretty convinced of the appeal of tech in the current market, and feel that in general it should be studied by retail investors. But we would think twice about XT. Quick Breakdown First let's discuss some of the features of XT. The mandate is to build a portfolio that weights towards a decent amount of emerging markets and emerging technologies that follow nine key themes. XT Nine Areas of Focus (iShares.com) The themes listed above are pretty basic to be honest. We all know of the potential in these fields, and in the majority of cases the value of things like cloud computing have already been realised, at least in terms of priced in value, by large corporations through already profitable operations. Essentially, what XT is doing is allocating to all the sexiest ideas in investing that VCs would typically be focusing on. As mentioned it's not all US markets with only 62% allocation, which is nice because foreign markets typically don't value tech nearly as highly as the US does, and it's mostly tech but also some healthcare exposures, especially biotechs. The fee is below 0.5%, which isn't bad relative to some of these more 'exciting' ETFs. The fact sheet says that it's cheaper than 91% of ETFs in its category, but this should be taken with a grain of salt because they decide the categories. What matters is many iShares ETFs are around 0.4%, so just below 0.5% isn't bad relatively. ETFs and Exponential Technologies However, we have some comments about the ETF. The first is that the kinds of businesses it invests in, especially in healthcare, are stocks that depend reflexively on the equity capital market conditions. If their stocks decline, the cost of their financing rises. This is obviously bad because in unstable markets like the current one, where rates will have to rise a lot more to deal with inflation, because it causes vicious spirals.

Recent updates

Seeking Alpha • Apr 10

XT: More Sensitive Than General Market To Cost Of Capital Changes

Summary The iShares Future Exponential Technologies ETF is highly sensitive to cost of capital shifts, driven by its tech and disruptor focus, also with a lot of high-multiple healthcare. XT's global diversification does not mitigate its vulnerability to rising rates and geopolitical risks, especially from the Iran conflict, which is having a global upward cost of capital shift effect. XT is less concentrated in mega-cap US tech than IVV, but its higher IT and healthcare exposure increases sensitivity to inflation and capital costs and maintains sensitivity to overbuild risks. We see more risks than supports for XT, given fragile geopolitics and amplified yield curve sensitivity. Lower multiple alternatives in equity markets often present less cost of capital sensitivity. Read the full article on Seeking Alpha
Seeking Alpha • Oct 06

XT: An Undervalued Portfolio Of Innovative Global Tech Stocks

Summary iShares Exponential Technologies ETF focuses on companies driving technological innovation across various sectors, offering diversified exposure to high-growth potential industries. The ETF's investment thesis is centered on capturing the growth of exponential technologies, including AI, robotics, and biotechnology, which are expected to transform industries. The fund looks appealing due to its diversified portfolio, evidential capacity to out-perform (albeit not since January 2021), and alignment with long-term technological trends. At present, XT has clear potential for a high IRR, with the potential for returns of circa 11% annualized over the next five years. Read the full article on Seeking Alpha
Seeking Alpha • Jun 07

XT Will Likely Continue Lagging The Broader IT Sector

Summary iShares Exponential Technologies ETF is a hold due to multiple risk factors outweighing its returns along with a relatively high expense ratio. XT lacks holdings with strong fundamentals and diversified revenue streams compared to peer tech funds, particularly Vanguard's VGT. XT also includes foreign tech holdings in emerging markets, representing geopolitical risks. Read the full article on Seeking Alpha
Seeking Alpha • Mar 10

XT: Still Beating ARKK At Its Own Game, Upgrade To Buy For Possible Moonshot

Summary iShares Exponential Technologies ETF is a go-to holding due to market volatility and potential for high returns. I prefer XT to the ARK Innovation ETF, given its smoother path due to a more diversified and passive/indexed approach. XT's lower volatility and diversified portfolio make it a buy, with potential for a price increase to its 2022 high and beyond. Read the full article on Seeking Alpha
Seeking Alpha • Aug 07

XT: We're Going To Think Twice About This ETF

XT is pretty interesting and tackles an area of the market that has received flak in the latest sell-offs. However, we have some concerns about approaching emerging technologies with ETFs. Also the fund isn't that discounted despite expected reflexivity effects. Might get better bets with specific stocks. The iShares Exponential Technologies ETF (XT) might seem broadly interesting at first, but we have some misgivings about the concept of investing in ETFs of higher risk businesses. Moreover, we are surprised by how well the ETF has done all things considered, and worry that some latent effects might still hit it. Otherwise, we are pretty convinced of the appeal of tech in the current market, and feel that in general it should be studied by retail investors. But we would think twice about XT. Quick Breakdown First let's discuss some of the features of XT. The mandate is to build a portfolio that weights towards a decent amount of emerging markets and emerging technologies that follow nine key themes. XT Nine Areas of Focus (iShares.com) The themes listed above are pretty basic to be honest. We all know of the potential in these fields, and in the majority of cases the value of things like cloud computing have already been realised, at least in terms of priced in value, by large corporations through already profitable operations. Essentially, what XT is doing is allocating to all the sexiest ideas in investing that VCs would typically be focusing on. As mentioned it's not all US markets with only 62% allocation, which is nice because foreign markets typically don't value tech nearly as highly as the US does, and it's mostly tech but also some healthcare exposures, especially biotechs. The fee is below 0.5%, which isn't bad relative to some of these more 'exciting' ETFs. The fact sheet says that it's cheaper than 91% of ETFs in its category, but this should be taken with a grain of salt because they decide the categories. What matters is many iShares ETFs are around 0.4%, so just below 0.5% isn't bad relatively. ETFs and Exponential Technologies However, we have some comments about the ETF. The first is that the kinds of businesses it invests in, especially in healthcare, are stocks that depend reflexively on the equity capital market conditions. If their stocks decline, the cost of their financing rises. This is obviously bad because in unstable markets like the current one, where rates will have to rise a lot more to deal with inflation, because it causes vicious spirals.

Aktionärsrenditen

XTUS Capital MarketsUS Markt
7D2.3%4.1%2.2%
1Y30.8%12.4%24.8%

Rendite im Vergleich zur Industrie: XT übertraf die Branche US Capital Markets , die im vergangenen Jahr eine Rendite von 12.4 erzielte.

Rendite vs. Markt: XT übertraf den Markt US, der im vergangenen Jahr eine Rendite von 24.8 erzielte.

Preisvolatilität

Is XT's price volatile compared to industry and market?
XT volatility
XT Average Weekly Movement3.1%
Capital Markets Industry Average Movement3.5%
Market Average Movement7.2%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.1%

Stabiler Aktienkurs: XT hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.

Volatilität im Zeitverlauf: XTDie wöchentliche Volatilität (3%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

GegründetMitarbeiterCEOWebsite
2015n/an/awww.ishares.com/us/products/272532/ishares-exponential-technologies-etf

iShares Trust - iShares Future Exponential Technologies ETF ist ein börsengehandelter Fonds, der von BlackRock, Inc. Der Fonds wird von BlackRock Fund Advisors verwaltet. Der Fonds investiert in öffentliche Aktienmärkte der globalen Region. Der Fonds investiert in Aktien von Unternehmen, die in verschiedenen Sektoren der Informationstechnologie tätig sind.

iShares Trust - iShares Future Exponential Technologies ETF's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von iShares Trust - iShares Future Exponential Technologies ETF im Vergleich zum Marktanteil des Unternehmens?
XT grundlegende Statistiken
MarktanteilUS$3.90b
Gewinn(TTM)US$0
Umsatz(TTM)n/a
n/a
Kurs-Gewinn-Verhältnis
n/a
Kurs-Umsatz-Verhältnis

Ist XT zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
XT Gewinn- und Verlustrechnung (TTM)
EinnahmenUS$0
Kosten der EinnahmenUS$0
BruttogewinnUS$0
Sonstige AusgabenUS$0
GewinnUS$0

Zuletzt gemeldete Gewinne

k.A.

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)0
Bruttomarge0.00%
Nettogewinnspanne0.00%
Schulden/Eigenkapital-Verhältnis0.0%

Wie hat sich XT auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Dividenden

6.5%
Aktuelle Dividendenrendite
n/a
Ausschüttungsquote

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/06/16 08:49
Aktienkurs zum Tagesende2026/06/15 00:00
GewinneN/A
Jährliche EinnahmenN/A

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

iShares Trust - iShares Future Exponential Technologies ETF wird von 0 Analysten beobachtet. 0 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.